Tag: Pivotal

Leverages AI to offer real-time support, raise service requests, and simplify complex transaction queries MUMBAI, India, July 23, 2025 /PRNewswire/ -- Axis Trustee Services Limited (ATSL),...

CEO Dr. Michael Fübi's visit reinforces India's growing role in shaping global compliance standards, sustainable industries, and future-ready workforce development. BANGALORE, India, July 23,...

ZUG, Switzerland, July 22, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), announced today the pricing of an underwritten offering of (i) 8,250,000 of its ordinary shares at a price of $20.00 per share and (ii) to one investor, pre-funded warrants to purchase 500,000 ordinary shares at a price of $19.99 per pre-funded warrant, which represents the per share public offering price for the ordinary shares less the $0.01 per share exercise price for each such pre-funded warrant. All shares and pre-funded warrants in the offering are to be sold by Pharvaris. In addition, Pharvaris has granted the underwriters a 30-day option to purchase up to an additional 1,312,500 ordinary shares at the public offering price, less underwriting discounts and commissions. The gross proceeds to Pharvaris from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $175 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about July 24, 2025, subject to satisfaction of customary closing conditions.

WOBURN, Mass., July 22, 2025 /PRNewswire/ -- Micro Medical Solutions (MMS), a leading innovator in minimally invasive vascular solutions for Critical Limb Ischemia (CLI),...

KIRKLAND, Wash., July 22, 2025 /PRNewswire/ -- Today, Northwest University (NU) announces the appointment of Jeremy Johnson, Ed.D, as President, effective August 18, 2025,...

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...

Naples CRE broker, Mike Rivera Secures Prime Office Space Listings in SWFL

Naples CRE broker, Mike Rivera Secures Prime Office Space Listings in SWFL

Modest Year-Over-Year Wholesale Cost Increases Expected in Most Areas, Some Areas See Decreases VALLEY FORGE, Pa., July 22, 2025 /PRNewswire/ -- PJM Interconnection today announced the...

NEW YORK, July 22, 2025 /PRNewswire/ -- From rapid advances in AI to geopolitical volatility and evolving workforce expectations, organizations are facing historic levels...

BOSTON, July 22, 2025 /PRNewswire/ -- In a new article published in Value in Health, researchers from Analysis Group, a global leader in health economics...

Accomplished Product and Strategy Executive joins Accruit's Senior Leadership Team to Drive Product Innovation and Advance Technology Strategy DENVER, July 22, 2025 /PRNewswire/ -- Accruit,...